275 related articles for article (PubMed ID: 26621482)
1. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.
Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Michaud K; Nyberg F; Pappas DA; Reed G; Tanaka E; Tran TN; Verstappen SM; Yamanaka H; Wesby-van Swaay E; Symmons D
Ann Rheum Dis; 2016 Oct; 75(10):1789-96. PubMed ID: 26621482
[TBL] [Abstract][Full Text] [Related]
2. Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.
Michaud K; Berglind N; Franzén S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Horne L; Inoue E; Nyberg F; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Askling J
Ann Rheum Dis; 2016 Oct; 75(10):1797-805. PubMed ID: 26857699
[TBL] [Abstract][Full Text] [Related]
3. Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme.
Yamanaka H; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Ho M; Holmqvist M; Novelli Horne L; Inoue E; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SMM; Wesby-van Swaay E; Nyberg F
RMD Open; 2017; 3(2):e000498. PubMed ID: 29081988
[TBL] [Abstract][Full Text] [Related]
4. Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.
Verstappen SM; Askling J; Berglind N; Franzen S; Frisell T; Garwood C; Greenberg JD; Holmqvist M; Horne L; Lampl K; Michaud K; Nyberg F; Pappas DA; Reed G; Symmons DP; Tanaka E; Tran TN; Yamanaka H; Ho M
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1637-45. PubMed ID: 26201948
[TBL] [Abstract][Full Text] [Related]
5. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD
Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866
[TBL] [Abstract][Full Text] [Related]
6. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment.
Simon TA; Smitten AL; Franklin J; Askling J; Lacaille D; Wolfe F; Hochberg MC; Qi K; Suissa S
Ann Rheum Dis; 2009 Dec; 68(12):1819-26. PubMed ID: 19054822
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.
Gross RL; Schwartzman-Morris JS; Krathen M; Reed G; Chang H; Saunders KC; Fisher MC; Greenberg JD; Putterman C; Mease PJ; Gottlieb AB; Kremer JM; Broder A
Arthritis Rheumatol; 2014 Jun; 66(6):1472-81. PubMed ID: 24591475
[TBL] [Abstract][Full Text] [Related]
8. Do rheumatoid arthritis and lymphoma share risk factors?: a comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis.
Hellgren K; Smedby KE; Feltelius N; Baecklund E; Askling J
Arthritis Rheum; 2010 May; 62(5):1252-8. PubMed ID: 20155827
[TBL] [Abstract][Full Text] [Related]
9. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
10. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives.
Ekström K; Hjalgrim H; Brandt L; Baecklund E; Klareskog L; Ekbom A; Askling J
Arthritis Rheum; 2003 Apr; 48(4):963-70. PubMed ID: 12687538
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?
Hellgren K; Baecklund E; Backlin C; Sundstrom C; Smedby KE; Askling J
Arthritis Rheumatol; 2017 Apr; 69(4):700-708. PubMed ID: 27992692
[TBL] [Abstract][Full Text] [Related]
13. The Risk of Malignancy in Korean Patients with Rheumatoid Arthritis.
Lee H
Yonsei Med J; 2019 Feb; 60(2):223-229. PubMed ID: 30666845
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register.
Askling J; Baecklund E; Granath F; Geborek P; Fored M; Backlin C; Bertilsson L; Cöster L; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; van Vollenhoven R; Klareskog L; Feltelius N
Ann Rheum Dis; 2009 May; 68(5):648-53. PubMed ID: 18467516
[TBL] [Abstract][Full Text] [Related]
15. The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.
Lin YC; Chou HW; Tsai WC; Yen JH; Chang SJ; Lin YC
Clin Rheumatol; 2015 Jul; 34(7):1195-202. PubMed ID: 25990004
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.
Askling J; Fored CM; Baecklund E; Brandt L; Backlin C; Ekbom A; Sundström C; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L; Feltelius N
Ann Rheum Dis; 2005 Oct; 64(10):1414-20. PubMed ID: 15843454
[TBL] [Abstract][Full Text] [Related]
17. Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma.
Baecklund E; Sundström C; Ekbom A; Catrina AI; Biberfeld P; Feltelius N; Klareskog L
Arthritis Rheum; 2003 Jun; 48(6):1543-50. PubMed ID: 12794821
[TBL] [Abstract][Full Text] [Related]
18. Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?
Holmqvist M; Ljung L; Askling J
Ann Rheum Dis; 2018 Jan; 77(1):85-91. PubMed ID: 28970218
[TBL] [Abstract][Full Text] [Related]
19. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts.
Holmqvist ME; Wedrén S; Jacobsson LT; Klareskog L; Nyberg F; Rantapää-Dahlqvist S; Alfredsson L; Askling J
Arthritis Rheum; 2009 Oct; 60(10):2861-9. PubMed ID: 19790058
[TBL] [Abstract][Full Text] [Related]
20. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
Raaschou P; Simard JF; Neovius M; Askling J;
Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
